GlassScriptPhysician profile
Harsimran Kaur
NPI 1134738479
$1,455.13
in general payments reported to CMS, 2019-2025
12 companies · $26.79 in 2025
The $26.79 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $77.58 · 2023: $702 · 2024: $448 · 2025: $26.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $192.77 | 2021-2025 | Activase, Tnkase |
| Emd Serono, INC. | $192.46 | 2023-2024 | Mavenclad |
| Sumitomo Pharma America, INC. | $151.82 | 2023 | Aptiom |
| Genzyme Corporation | $145.49 | 2023 | |
| Janssen Pharmaceuticals, INC | $131.25 | 2024 | Xarelto |
| Abbvie INC. | $125.69 | 2023 | |
| Ucb, INC. | $118.67 | 2021-2024 | Fintepla |
| Pfizer INC. | $115.90 | 2023-2024 | |
| Livanova USA, INC. | $113.46 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $104.50 | 2021 | |
| Argenx US, INC. | $42.77 | 2022-2023 | Vyvgart |
| Amylyx Pharmaceuticals, INC. | $20.35 | 2023 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsimran Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.